The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Atletico Madrid will have to pick themselves up as they prepare to host Barcelona in a top-of-the-table LaLiga clash on ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

Novartis, a leading innovative medicines company, and the National Football League (NFL) announced an unprecedented partnership that names Novartis as the official first-in-category corporate ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

Novartis, a pharmaceuticals company, and the National Football League have announced an unprecedented partnership that names Novartis as the official first-in-category corporate pharmaceutical partner ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

The NFL has inked a multi-year deal with pharmaceutical giant Novartis, marking its first such partnership. This ...

The exclusive negotiating window for Visa, a 30-year NFL sponsor, to renew its deal with the league has expired, and the NFL ...

Novartis AG (NYSE:NVS – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 54,767 call options on the stock. This represents an increase of 2,389% ...